Moderna Inc is looking at recording sales of about $18.5 billion in 2022 from contracts for its COVID-19 vaccine.
Moderna also expects to rake in about $3.5 billion from potential additional purchases including booster candidates updated for variants.
The company in November said its sales could be in the range of $17 billion to $22 billion in 2022.
Moderna is in active discussions for additional COVID-19 vaccine contracts this year.
Moderna is also developing a booster vaccine candidate, called mRNA-1273.529.
mRNA-1273.529 targets the fast-spreading Omicron variant. Moderna expects it to advance into clinical trials in early 2022.